The stock will trade at or near the $73 cash acquisition price until deal close, with the primary risk being regulatory or shareholder approval delays. The earnings release is largely a procedural update — the acquisition terms dominate the investment thesis. Monitor for regulatory clearance milestones and any competing bids.
Price Chart
Executive Summary
Bio-Techne reported Q4 FY2026 results with organic revenue growth of 3% (reported +1% to $321.2M), GAAP EPS of $0.35 vs $(0.11) a year ago, and adjusted EPS of $0.52 vs $0.53 a year ago. The company also declared a $0.08/share quarterly dividend. However, the primary event is the previously announced agreement to be acquired by Merck KGaA for $73/share in cash (~$11.3B enterprise value), making this earnings release largely procedural as the company is no longer holding investor conference calls for quarterly results. The acquisition premium and deal certainty dominate the stock's trajectory, rendering the modest adjusted EPS decline and flat full-year revenue as secondary considerations.
Key Financial Metrics
Key Facts
- Bio-Techne entered into an agreement to be acquired by Merck KGaA, Darmstadt, Germany for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion.
- Q4 FY2026 organic revenue increased 3% (reported +1% to $321.2M); full-year revenue flat at $1.2 billion.
- Q4 GAAP EPS was $0.35 vs $(0.11) a year ago; adjusted EPS was $0.52 vs $0.53 a year ago.
- Full-year GAAP EPS was $1.16 vs $0.46; full-year adjusted EPS was $1.93 vs $1.92.
- Bio-Techne declared a quarterly dividend of $0.08 per share, payable September 4, 2026.
- In light of the announced transaction, Bio-Techne is no longer holding investor conference calls for quarterly results.
Financial Impact
Acquisition at $73/share represents a premium to the pre-announcement stock price, with total enterprise value of ~$11.3B. Q4 revenue of $321.2M and adjusted EPS of $0.52 are in line with expectations.
Risk Factors
- Regulatory or antitrust delays in closing the Merck KGaA acquisition
- Shareholder vote failure or emergence of a competing bid at a lower price
- Material adverse change or termination of the merger agreement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-094391 |
| Document: tech-20260812x8k.htm | 0001104659-26-094391 |
| Document: tech-20260812xex99d2.htm | 0001104659-26-094391 |
| Document: 0001104659-26-094391-index-headers.html | 0001104659-26-094391 |
| Document: 0001104659-26-094391-index.html | 0001104659-26-094391 |
| Document: 0001104659-26-094391.txt | 0001104659-26-094391 |
| 8-K Data (Synthetic) | 0001104659-26-094391 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | 8-K | $72.23 $72.08 | ▼ −0.21% | ▲ +1.69% | $72.42 (+0.26%) |
Aug 12, 2026 7w ago | Press Release | $72.23 $72.08 | ▼ −0.21% | ▲ +1.69% | $72.42 (+0.26%) |
Aug 10, 2026 7w ago | PREM14A | $72.15 $72.25 | ▲ +0.14% | ▲ +1.20% | $72.42 (+0.37%) |
Jun 25, 2026 14w ago | DEFA14A | $71.00 $71.77 | ▲ +1.08% | ▼ −0.18% | $72.42 (+1.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access